Press coverage about Arca Biopharma (NASDAQ:ABIO) has been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Arca Biopharma earned a news impact score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.4985299550856 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, ValuEngine raised Arca Biopharma from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Shares of Arca Biopharma traded down $0.02, hitting $0.66, during trading hours on Friday, Marketbeat.com reports. 271,387 shares of the company’s stock traded hands, compared to its average volume of 2,211,312. Arca Biopharma has a 12-month low of $0.45 and a 12-month high of $2.00.
Arca Biopharma Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction.
Recommended Story: What is the NASDAQ Stock Market?
Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.